Latest news with #Attruby
Yahoo
13 hours ago
- Business
- Yahoo
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best Russell 2000 stocks to buy now. On August 6, TD Cowen reiterated its 'Buy' rating on BridgeBio stock and maintained a price target of $60. TD Cowen cited the strong performance of BridgeBio's drug Attruby, whose sales doubled in the second full quarter of availability, as the primary factor in its decision. The other reason the firm cited was the accelerating rate of new prescriptions per week. Pressmaster/ TD Cowen noted that gross-to-net discounts increased from 25% to over 35%, while free drug programs expanded from 45% to between 70% and 80%. The firm considers the improvements as an 'indicator of first-line usage.' It also observed some utilization of patient assistance programs, with these metrics now stabilizing. TD Cowen projected that the increase in free drug patients quarter-over-quarter will drive sales growth, adding that the drug with the best point estimates and lowest price will ultimately prevail in the $10-20 billion drug category managed by insurance companies over time. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company. It develops and commercializes therapies for genetic diseases and cancers with clear genetic drivers. The company's pipeline includes treatments for conditions such as transthyretin amyloidosis, achondroplasia, and various rare metabolic disorders. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Energy Stocks to Buy For the Long Term and Top 10 Industrial Stocks to Buy Amid Easing Tariff Uncertainties. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
06-08-2025
- Business
- Yahoo
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ...
Total Revenue: $110.6 million in Q2 2025, up from $2.2 million in the same period last year. Attruby Net Product Revenue: $71.5 million in U.S. net sales, representing 100% growth over Q1 2025. Royalty Revenue: $1.6 million from ex-U.S. net sales in Europe and Japan. License and Services Revenue: Increased by $35.3 million, including a $30 million regulatory milestone. Operating Costs and Expenses: $244.8 million in Q2 2025, up from $177.7 million in the same period last year. SG&A Expenses: Increased by $69.6 million. R&D Expenses: Declined by $3.5 million. Stock-Based Compensation Expense: $37.7 million, up from $21.5 million in Q2 2024. Cash Position: $756.9 million in cash, cash equivalents, and marketable securities. Attruby Prescriptions: 3,751 unique patient prescriptions and 1,074 unique prescribers. Weekly Script Growth: Over 30% growth in weekly scripts. New Patient Adds: Around 120 patients per week. Warning! GuruFocus has detected 8 Warning Signs with BBIO. Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BridgeBio Pharma Inc (NASDAQ:BBIO) reported strong growth in the launch of Attruby, with 100% revenue growth in Q2, reaching $78 million in global sales. The company has seen a significant increase in unique patient prescriptions for Attruby, with over 3,751 prescriptions and 1,074 unique prescribers. Attruby has demonstrated remarkable efficacy, with a 59% hazard reduction in time to first event in the variant population and a 43% reduction in risk of cardiac arrhythmia-related hospitalizations. BridgeBio Pharma Inc (NASDAQ:BBIO) has a strong cash position of $756.9 million, providing financial flexibility for future growth and development. The company is poised to become a diversified biopharma with up to three novel best or first-in-class assets in high unmet need areas, each representing billion-plus dollar opportunities. Negative Points Operating costs and expenses increased by $67.1 million compared to the same period last year, driven by a $69.6 million increase in SG&A expenses. The company faces competition in the ATTR cardiomyopathy market, particularly from Pfizer and Alnylam, which could impact market share. There is pressure on the switch category from competitors, particularly from knockdown agents, which could affect Attruby's growth. The market for some of BridgeBio Pharma Inc (NASDAQ:BBIO)'s pipeline products, such as ADH1, is poorly characterized and underdiagnosed, which could pose challenges in market penetration. The company is investing heavily in late-stage clinical programs, which could strain financial resources if expected outcomes are not achieved. Q & A Highlights Q: Can you break down the factors driving the increase in patient adds for Attruby, and how do you envision this trend changing in the upcoming quarters? A: Matthew Outten, Chief Commercial Officer: We're seeing strength in treatment-naive starts and continued switch activity. The market is expanding due to increased screening and awareness. Unique patient starts and prescriber counts are both increasing, making BridgeBio the partner of choice for healthcare professionals. The Attruby profile resonates with both patients and doctors, offering benefits as soon as 3 months and a 50% reduction in hospitalization rates. Neil Kumar, CEO: It's hard to tell the exact NBRx share, but it's estimated to be in the 18% to 20% range and growing. Better access and increasing scientific share of voice are driving commercial momentum. Q: How did the trends for the 28-day free trial, patient assistance programs, and gross to net evolve in the second quarter compared to the first quarter? A: Neil Kumar, CEO: We saw normalization in all three areas. The variant data showing the highest risk reduction in the V122I population and the broad variant population is crucial for serving underpenetrated populations with ATTR cardiomyopathy. These programs are important for reaching communities that have been historically underserved. We believe that our pricing and access programs will benefit us in the long term. Q: Can you discuss the community versus academic market share for Attruby and the potential market share for infigratinib in hypochondroplasia? A: Matthew Outten, Chief Commercial Officer: The overall data package combined with unmet need is driving growth. Patients are looking for effective treatments, and Attruby meets those needs. The market is growing as more people are diagnosed. Justin To, CEO, Skeletal Dysplasias: For infigratinib, we aim to provide a daily oral treatment option with deeper efficacy by targeting both the MAPK pathway and STAT1. Market research shows an oral treatment with similar efficacy could capture about 60% of the market. Q: What would be considered a meaningful win in the upcoming Phase 3 CALIBRATE trial for encaleret? A: Ananth Sridhar, COO, Cardiorenal: A successful study would be a home run for the ADH1 community. The available conventional therapy offers meager benefits, so achieving normalization of both blood and urine calcium would be a significant step forward. In our Phase 2 cohort, 69% of participants achieved normalization on encaleret, compared to 0% on standard care. Q: How do you plan to leverage the data to convince payers and doctors to use Attruby more in the first-line setting? A: Neil Kumar, CEO: We are increasing our scientific share of voice through conferences, publications, and real-world evidence studies. The recent data on variant populations, AFib, and serum TTR levels are key differentiators. We are also focusing on the rapidity of response and real-world experience to highlight Attruby's benefits. Q: What are the areas for growth within the Attruby launch, and what is BridgeBio excited about for the remainder of the year? A: Neil Kumar, CEO: We're excited about the continued clinical differentiation and the concept of early impact and efficacy. The prevention study and rapid stabilization of serum TTR levels are key areas of focus. We're also working on improving access and support programs to ensure that anyone who wants Attruby can get it. Q: What is resonating with new prescribers and repeat prescribing dynamics for Attruby? A: Matthew Outten, Chief Commercial Officer: When HCPs see how quickly Attruby works, it reinforces their decision to prescribe it. The efficacy and support programs have made a significant impact. This is important in both community and academic settings, leading to continued growth in prescriber numbers. Q: How does success in ADH1 translate to hypoparathyroidism, and how do you view responder rates compared to existing therapies? A: Ananth Sridhar, COO, Cardiorenal: ADH1 is the most common genetic subset of hypoparathyroidism, so a positive study would de-risk further evaluation in chronic hypoparathyroidism. Rapid and durable benefits on blood and urine calcium, along with safety, are key aspects. In our Sentinel study, 80% of participants normalized blood and urine calcium within 5 days of dosing with encaleret. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
12-06-2025
- Business
- Yahoo
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock's buy rating. A team of scientists in white lab coats reviewing lab results in a research facility. Positive momentum for the company is proven by the fast uptake of the Attruby product, which is the driving force behind this bullish forecast. For adult patients with ATTR-CM, Attruby is the only nearly full (≥90%) stabilizer of Transthyretin (TTR) that has been approved in the United States to lower cardiovascular mortality and hospitalizations linked to cardiovascular disease. In general, Attruby was highly received. Abdominal pain and diarrhea were the most frequent, moderate side effects that went away without stopping the medication. BridgeBio Pharma, Inc. (NASDAQ:BBIO) provides a wide range of initiatives to facilitate patients' access to our medications. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a novel biopharmaceutical business that was established to find, develop, test, and distribute revolutionary medications to treat people with hereditary disorders. The development programs in its pipeline span from early science to advanced clinical trials. BBIO is among the stocks with the biggest upside. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock's buy rating. A team of scientists in white lab coats reviewing lab results in a research facility. Positive momentum for the company is proven by the fast uptake of the Attruby product, which is the driving force behind this bullish forecast. For adult patients with ATTR-CM, Attruby is the only nearly full (≥90%) stabilizer of Transthyretin (TTR) that has been approved in the United States to lower cardiovascular mortality and hospitalizations linked to cardiovascular disease. In general, Attruby was highly received. Abdominal pain and diarrhea were the most frequent, moderate side effects that went away without stopping the medication. BridgeBio Pharma, Inc. (NASDAQ:BBIO) provides a wide range of initiatives to facilitate patients' access to our medications. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a novel biopharmaceutical business that was established to find, develop, test, and distribute revolutionary medications to treat people with hereditary disorders. The development programs in its pipeline span from early science to advanced clinical trials. BBIO is among the stocks with the biggest upside. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
BridgeBio price target raised to $42 from $37 at BMO Capital
BMO Capital raised the firm's price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby's U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on BBIO: Disclaimer & DisclosureReport an Issue Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating BridgeBio presents data from ATTRibute-CM BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential BridgeBio announces first participant dosed with acoramidis in ACT-EARLY Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
